Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes

Virology

Volumn 387, Issue 2, 2009, Pages 380-387

  Muench, Peter ^a   Hiller, Thomas ^a   Probst, Sonja ^a   Florea, Ana Maria ^a   Stubenrauch, Frank ^a   Iftner, Thomas ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cervical cancer; E6 protein; hDlg; HPV; MAGI1; Risk classification

Indexed keywords

ONCOPROTEIN; PDZ PROTEIN; PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN HDLG; PROTEIN MAGI1; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ARTICLE; CARCINOGENICITY; CELL IMMORTALIZATION; HPV 66; HPV 70; HPV 82; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOFLUORESCENCE TEST; KERATINOCYTE; NONHUMAN; PREPUCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; WART VIRUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL ADHESION MOLECULES, NEURONAL; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; FEMALE; FORESKIN; GENES, TUMOR SUPPRESSOR; HUMANS; KERATINOCYTES; MALE; MEMBRANE PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PDZ DOMAINS; PROTEIN BINDING; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 66649131531     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.02.018     Document Type: Article

References (41)

1. Bedard K.M., Underbrink M.P., Howie H.L., and Galloway D.A. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J. Virol. 82 8 (2008) 3894-3902
2. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6 4 (2005) 204
3. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 1 (2004) 17-27
4. Dobrosotskaya I.Y., and James G.L. MAGI-1 interacts with beta-catenin and is associated with cell-cell adhesion structures. Biochem. Biophys. Res. Commun. 270 3 (2000) 903-909
5. Elbel M., Carl S., Spaderna S., and Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 239 1 (1997) 132-149
6. Foster S.A., Demers G.W., Etscheid B.G., and Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68 9 (1994) 5698-5705
7. Frattini M.G., Lim H.B., and Laimins L.A. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl. Acad. Sci. U. S. A. 93 7 (1996) 3062-3067
8. Gardiol D., Kuhne C., Glaunsinger B., Lee S.S., Javier R., and Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18 40 (1999) 5487-5496
9. Gewin L., Myers H., Kiyono T., and Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18 18 (2004) 2269-2282
10. Glaunsinger B.A., Lee S.S., Thomas M., Banks L., and Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19 46 (2000) 5270-5280
11. Halbert C.L., Demers G.W., and Galloway D.A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65 1 (1991) 473-478
12. Herrero R., Castle P.E., Schiffman M., Bratti M.C., Hildesheim A., Morales J., Alfaro M., Sherman M.E., Wacholder S., Chen S., Rodriguez A.C., and Burk R.D. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis. 191 11 (2005) 1796-1807
13. Hiller T., Poppelreuther S., Stubenrauch F., and Iftner T. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomark. Prev. 15 7 (2006) 1262-1267
14. Ishidate T., Matsumine A., Toyoshima K., and Akiyama T. The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase. Oncogene 19 3 (2000) 365-372
15. James M.A., Lee J.H., and Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 80 11 (2006) 5301-5307
16. Kelley M.L., Keiger K.E., Lee C.J., and Huibregtse J.M. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol. 79 6 (2005) 3737-3747
17. Kiyono T., Hiraiwa A., Fujita M., Hayashi Y., Akiyama T., and Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94 21 (1997) 11612-11616
18. Klingelhutz A.J., Foster S.A., and McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380 6569 (1996) 79-82
19. Kotelevets L., van Hengel J., Bruyneel E., Mareel M., van Roy F., and Chastre E. Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J. 19 1 (2005) 115-117
20. Kuballa P., Matentzoglu K., and Scheffner M. The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J. Biol. Chem. 282 1 (2007) 65-71
21. Laprise P., Viel A., and Rivard N. Human homolog of disc-large is required for adherens junction assembly and differentiation of human intestinal epithelial cells. J. Biol. Chem. 279 11 (2004) 10157-10166
22. Lee C., and Laimins L.A. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J. Virol. 78 22 (2004) 12366-12377
23. Lee S.S., Weiss R.S., and Javier R.T. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 94 13 (1997) 6670-6675
24. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., Kelley M.L., Baker C.C., Huibregtse J., and Schlegel R. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 280 11 (2005) 10807-10816
25. Mansour M., Touka M., Hasan U., Bellopede A., Smet A., Accardi R., Gabet A.S., Sylla B.S., and Tommasino M. E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development. Virology 367 1 (2007) 1-9
26. Munger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 89 2 (2002) 213-228
27. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., and Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8 13 (1989) 4099-4105
28. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., and Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 21 (2004) 11451-11460
29. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., and Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 6 (2003) 518-527
30. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 Suppl 3 (2006) S3/1-10
31. Nakagawa S., and Huibregtse J.M. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol. Cell. Biol. 20 21 (2000) 8244-8253
32. Narechania A., Chen Z., DeSalle R., and Burk R.D. Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses. J. Virol. 79 24 (2005) 15503-15510
33. Nguyen M.L., Nguyen M.M., Lee D., Griep A.E., and Lambert P.F. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J. Virol. 77 12 (2003) 6957-6964
34. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 6 (1990) 1129-1136
35. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., and Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 3 (2007) 621-632
36. Spanos W.C., Geiger J., Anderson M.E., Harris G.F., Bossler A.D., Smith R.B., Klingelhutz A.J., and Lee J.H. Deletion of the PDZ motif of HPV16 E6 preventing immortalization and anchorage-independent growth in human tonsil epithelial cells. Head Neck 30 2 (2008) 139-147
37. Thomas M., Massimi P., Navarro C., Borg J.P., and Banks L. The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24 41 (2005) 6222-6230
38. Wise-Draper T.M., and Wells S.I. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci. 13 (2008) 1003-1017
39. Zhang B., Chen W., and Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Natl. Acad. Sci. U. S. A. 103 2 (2006) 437-442
40. Zhang Y., Dasgupta J., Ma R.Z., Banks L., Thomas M., and Chen X.S. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J. Virol. 81 7 (2007) 3618-3626
41. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev., Cancer 2 5 (2002) 342-350